Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer
Abstract
Safety is a central consideration when choosing between multiple medications with similar efficacy. We aimed to evaluate whether adverse event (AE) profiles of 3 such drugs in advanced prostate cancer could be distinguished based on published literature.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 28, 2020
- Source ID
- 10.1093/jnci/djaa134
Entities
People
- Chana A. Sacks
- Gita Thanarajasingam
- Joshua Z. Drago
- Konrad H Stopsack
- Michael J. Morris
- Mithat Gönen
- Philip W. Kantoff
Organizations
- Massachusetts General Hospital
- Mayo Clinic
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- Prostate Cancer Foundation
- United States Department of Defense
- Weill Cornell Medicine